| scholarly article | Q13442814 |
| P2093 | author name string | Bertino JS Jr | |
| Nafziger AN | |||
| Traynor AM | |||
| P2860 | cites work | Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia | Q70386358 |
| Amikacin pharmacokinetics in morbidly obese patients | Q71202599 | ||
| Lean body mass in obesity | Q71765467 | ||
| Prediction of creatinine clearance from serum creatinine | Q29615603 | ||
| Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring | Q34061646 | ||
| Variation in the pharmacokinetics of gentamicin and tobramycin in patients with pleural effusions and hypoalbuminemia | Q35867409 | ||
| Gentamicin pharmacokinetics in patients with malignancies | Q36754353 | ||
| Drug metabolism and pharmacokinetics in malnourished children | Q38756087 | ||
| Basic pharmacokinetics | Q39731021 | ||
| Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients | Q40838757 | ||
| The 10-year incidence of overweight and major weight gain in US adults | Q43844390 | ||
| Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 | ||
| Alterations in aminoglycoside volume of distribution in patients below ideal body weight | Q47198985 | ||
| The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. | Q52695343 | ||
| Effect of Obesity on Gentamicin Pharmacokinetics | Q59157843 | ||
| Pharmacokinetics of gentamicin in malnourrished infants | Q64948136 | ||
| Tobramycin pharmacokinetics in morbidly obese patients | Q66940725 | ||
| A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects | Q67404922 | ||
| Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients | Q67779622 | ||
| Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides | Q69510690 | ||
| Relationship between body mass indices and measures of body adiposity | Q69562245 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 545-548 | |
| P577 | publication date | 1995-02-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Aminoglycoside dosing weight correction factors for patients of various body sizes | |
| P478 | volume | 39 |
| Q90260897 | A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients |
| Q43576827 | A dose-ranging study of gentamicin pharmacokinetics: implications for extended interval aminoglycoside therapy |
| Q40689023 | A study to evaluate the first dose of gentamicin needed to achieve a peak plasma concentration of 30 mg/l in patients hospitalized for severe sepsis. |
| Q36278432 | Adjusted body weight, con: why adjust body weight in energy-expenditure calculations? |
| Q43532401 | Adjustment of dosing of antimicrobial agents for bodyweight in adults. |
| Q93085292 | Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize A Priori Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients |
| Q64129066 | Aminoglycoside Dosing in Obesity |
| Q72336039 | Aminoglycosides |
| Q34075909 | Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance |
| Q47871375 | Approaches for optimising intravenous iron dosing in pregnancy: a retrospective cohort study. |
| Q45086694 | Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia |
| Q33770248 | Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation |
| Q37838126 | Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant Acinetobacter? |
| Q37590845 | Clinical pharmacokinetics and pharmacodynamics of tigecycline |
| Q45191658 | Comparative evaluation of the Cockcroft-Gault Equation and the Modification of Diet in Renal Disease (MDRD) study equation for drug dosing: an opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy |
| Q33937527 | Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics |
| Q30362353 | Dosing of antibacterial agents in obese adults: does one size fit all? |
| Q35587926 | Dosing of medications in morbidly obese patients in the intensive care unit setting |
| Q38907793 | Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options). |
| Q37778872 | Drug disposition in obesity and protein-energy malnutrition |
| Q29006722 | Evaluation of extended interval dosing aminoglycosides in the morbidly obese population |
| Q50319655 | High-dose amikacin for achieving serum target levels in critically ill elderly patients. |
| Q44321061 | Impact of small-for-gestational age (SGA) status on gentamicin pharmacokinetics in neonates |
| Q36034231 | Improving dosing of gentamicin in the obese patient: a 3-cycle drug chart and case note audit |
| Q61812041 | Improving peak concentrations of a single dose regime of gentamicin in patients with sepsis in the emergency department |
| Q42908869 | Management of Aminoglycosides in the Intensive Care Unit |
| Q34162361 | Management of the obese critically ill patient |
| Q52381647 | Measurement of Skeletal Muscle Area Improves Estimation of Aminoglycoside Clearance Across Body Size. |
| Q36247129 | Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing. |
| Q56928143 | Perioperative Antibiotics |
| Q35623060 | Pharmacodynamics and dosing of aminoglycosides |
| Q29248398 | Pharmacokinetic Changes and Dosing Modification of Aminoglycosides in Critically Ill Obese Patients: A Literature Review |
| Q35688447 | Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases |
| Q33855312 | Pharmacokinetics of Antimicrobials in Obese Children |
| Q35136143 | Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing. |
| Q33624977 | Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing |
| Q42633482 | Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus |
| Q33995500 | Preventing surgical site infections after bariatric surgery: value of perioperative antibiotic regimens. |
| Q40107546 | Recording inpatient weight: implications for medicines administration. |
| Q35629713 | Resuscitation of the morbidly obese patient |
| Q33919190 | Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock |
| Q35191383 | Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients |
| Q73799751 | Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing |
| Q47180268 | Study of relationship between volume of distribution and body weight application to amikacin |
| Q37580823 | The Prevention of Periprosthetic Joint Infections |
| Q33754166 | Therapeutic drug monitoring of amikacin in septic patients. |
| Q36111191 | Therapeutic drug monitoring to adjust dosing in morbid obesity - a new use for an old methodology |
| Q47179401 | What is the best size predictor for dose in the obese child? |
Search more.